GoAI
Get started
Addex Therapeutics Ltd logo

Addex Therapeutics Ltd

ADXN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.94

+$0.37 · +8.10%

Aug 21, 4:00 PM ET

ADXN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Strong Sell

Exit — multiple negative signals converging

Valuation

2

Overpriced

Momentum

31

Weakening

Sentiment

45

Mixed

Risk resilience

18

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CH
CEO
Timothy Mark Dyer
Listed since
Feb 12, 2020
Employees
3

Market position

Day range

Current $4.94

52-week range

Current $4.94

Open
$5.87
Previous close
$4.57
Volume
7.27M
2,493.38× average
Average volume
2.92K
Average daily volume
Market cap
6.09M USD
Beta
2
Market reference 1
50-day average
$5.8526
-15.59% below average
200-day average
$6.989
-29.32% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.12M CHF
P/E (TTM)
-0.63×
P/B (TTM)
1.82×
P/S (TTM)
59.32×
EV / EBITDA
-0.6×
Earnings yield
-117.52%
Free cash flow yield
-36.26%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
84.32%
Operating margin
-2999.71%
Net margin
-7775.20%
Return on equity
-141.14%
Return on assets
-105.68%
Return on invested capital
-54.40%

Financial health

Debt / equity
0.03×
Current ratio
1.4×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends4165%-5512%-15190%-24868%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -531.70%Operating margin, FY2022: -741.04%Operating margin, FY2023: -139.06%Operating margin, FY2024: -681.82%Operating margin, FY2025: -9390.76%Net margin, FY2021: -526.42%Net margin, FY2022: -1462.57%Net margin, FY2023: -654.47%Net margin, FY2024: 1746.04%Net margin, FY2025: -22448.44%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -531.70%. Operating margin FY2022 -741.04%. Operating margin FY2023 -139.06%. Operating margin FY2024 -681.82%. Operating margin FY2025 -9390.76%. Net margin FY2021 -526.42%. Net margin FY2022 -1462.57%. Net margin FY2023 -654.47%. Net margin FY2024 1746.04%. Net margin FY2025 -22448.44%.

Income trends

Revenue

29.97K CHF-92.58%

Operating income

−2.81M CHF-2.15%

Net income

−6.73M CHF−13.78M CHF
Income trends across reported periods9.84M CHF−1.3M CHF−12.45M CHF−23.59M CHFRevenue, FY2021: 2.92M CHFRevenue, FY2022: 1.42M CHFRevenue, FY2023: 1.61M CHFRevenue, FY2024: 404.1K CHFRevenue, FY2025: 29.97K CHFOperating income, FY2021: −15.51M CHFOperating income, FY2022: −10.54M CHFOperating income, FY2023: −2.24M CHFOperating income, FY2024: −2.76M CHFOperating income, FY2025: −2.81M CHFNet income, FY2021: −15.35M CHFNet income, FY2022: −20.8M CHFNet income, FY2023: −10.56M CHFNet income, FY2024: 7.06M CHFNet income, FY2025: −6.73M CHFFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.92M CHF. Revenue FY2022 1.42M CHF. Revenue FY2023 1.61M CHF. Revenue FY2024 404.1K CHF. Revenue FY2025 29.97K CHF. Operating income FY2021 −15.51M CHF. Operating income FY2022 −10.54M CHF. Operating income FY2023 −2.24M CHF. Operating income FY2024 −2.76M CHF. Operating income FY2025 −2.81M CHF. Net income FY2021 −15.35M CHF. Net income FY2022 −20.8M CHF. Net income FY2023 −10.56M CHF. Net income FY2024 7.06M CHF. Net income FY2025 −6.73M CHF.
Metric (CHF)FY2025FY2024FY2023FY2022FY2021
Revenue29.97K CHF404.1K CHF1.61M CHF1.42M CHF2.92M CHF
Gross profit29.97K CHF404.1K CHF1.61M CHF1.42M CHF2.92M CHF
Research and development190.19K CHF435.19K CHF942.71K CHF7.88M CHF9.01M CHF
Selling, general, and administrative1.89M CHF1.68M CHF2.03M CHF3.26M CHF7.75M CHF
Operating expenses2.84M CHF3.16M CHF3.86M CHF11.96M CHF18.42M CHF
Interest income—9.17K CHF63.96K CHF29.25K CHF5.32K CHF
Interest expense2.42K CHF3.55K CHF21.61K CHF48.9K CHF63.01K CHF
Depreciation and amortization8.47K CHF260.12K CHF305.95K CHF323.14K CHF347.61K CHF
Operating income−2.81M CHF−2.76M CHF−2.24M CHF−10.54M CHF−15.51M CHF
Net income−6.73M CHF7.06M CHF−10.56M CHF−20.8M CHF−15.35M CHF

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
11%
1 beat, 8 misses, 0 met estimates
Average EPS surprise
-2011.04%
9 comparable reports
Latest EPS result
-1.53

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.01-1.54-3.07-4.6Q3 '24MissQ4 '24MissQ2 '25MissQ2 '25BeatQ4 '25MissQ4 '25No estimateQ2 '26MissQ2 '26No estimate
Q3 2024, reported Sep 30, 2024: actual -1.77, estimate -0.01, surprise -17600.00%, Miss. Q4 2024, reported Nov 22, 2024: actual -2.77, estimate -1.4, surprise -97.86%, Miss. Q2 2025, reported Apr 7, 2025: actual -1.63, estimate -1.42, surprise -14.71%, Miss. Q2 2025, reported Jun 20, 2025: actual -1.33, estimate -4.26, surprise +68.77%, Beat. Q4 2025, reported Nov 10, 2025: actual -2.91, estimate -1.42, surprise -104.37%, Miss. Q4 2025, reported Dec 4, 2025: actual -1.5, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 30, 2026: actual -1.94, estimate -1.42, surprise -36.00%, Miss. Q2 2026, reported Jun 25, 2026: actual -1.53, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates337.91K225.74K113.58K1.41KQ3 '24MissQ4 '24MissQ2 '25MissQ2 '25EstimateQ4 '25MissQ4 '25MissQ2 '26BeatQ2 '26No estimate
Q3 2024, reported Sep 30, 2024: actual 128.66K USD, estimate 260K USD, surprise -50.52%, Miss. Q4 2024, reported Nov 22, 2024: actual 62.72K USD, estimate 150K USD, surprise -58.18%, Miss. Q2 2025, reported Apr 7, 2025: actual 1.66K USD, estimate 150K USD, surprise -98.89%, Miss. Q2 2025, reported Jun 20, 2025: actual —, estimate 236.62K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 10, 2025: actual 45.25K USD, estimate 236.62K USD, surprise -80.88%, Miss. Q4 2025, reported Dec 4, 2025: actual 37.36K USD, estimate 236.62K USD, surprise -84.21%, Miss. Q2 2026, reported Apr 30, 2026: actual 313K USD, estimate 236.62K USD, surprise +32.28%, Beat. Q2 2026, reported Jun 25, 2026: actual 9.88K USD, estimate —, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$30.00

507.29% upside
Past 12 months12-month forecastHigh $30.00Average $30.00Low $30.00

ADXN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ADXN

research.disclaimer